These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 16130895)

  • 21. The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer.
    Gubbi A; Kendrick JE; Finkler NJ
    Expert Rev Anticancer Ther; 2014 Oct; 14(10):1105-13. PubMed ID: 25189201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiogenesis as a therapeutic target in urothelial carcinoma.
    Pinto A; Redondo A; Zamora P; Castelo B; Espinosa E
    Anticancer Drugs; 2010 Nov; 21(10):890-6. PubMed ID: 20729712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
    Jain RK
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer.
    Tomao F; Papa A; Rossi L; Caruso D; Zoratto F; Benedetti Panici P; Tomao S
    Expert Opin Investig Drugs; 2014 Jan; 23(1):37-53. PubMed ID: 24111925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells.
    Wang Z; Banerjee S; Kong D; Li Y; Sarkar FH
    Cancer Res; 2007 Sep; 67(17):8293-300. PubMed ID: 17804744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vasohibin-2 expressed in human serous ovarian adenocarcinoma accelerates tumor growth by promoting angiogenesis.
    Takahashi Y; Koyanagi T; Suzuki Y; Saga Y; Kanomata N; Moriya T; Suzuki M; Sato Y
    Mol Cancer Res; 2012 Sep; 10(9):1135-46. PubMed ID: 22826464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers.
    Kryczek I; Lange A; Mottram P; Alvarez X; Cheng P; Hogan M; Moons L; Wei S; Zou L; Machelon V; Emilie D; Terrassa M; Lackner A; Curiel TJ; Carmeliet P; Zou W
    Cancer Res; 2005 Jan; 65(2):465-72. PubMed ID: 15695388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
    Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
    Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The vascular endothelial growth factor (VEGF): a model of gene regulation and a marker of tumour aggressiveness. An obvious therapeutic target?].
    Grépin R; Pagès G
    J Soc Biol; 2009; 203(2):181-92. PubMed ID: 19527632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer: The nuances of therapy.
    Ellis LM; Reardon DA
    Nature; 2009 Mar; 458(7236):290-2. PubMed ID: 19295595
    [No Abstract]   [Full Text] [Related]  

  • 31. Genes that regulate metastasis and angiogenesis.
    Webb CP; Vande Woude GF
    J Neurooncol; 2000; 50(1-2):71-87. PubMed ID: 11245283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiogenesis as targeted breast cancer therapy.
    Hayes DF; Miller K; Sledge G
    Breast; 2007 Dec; 16 Suppl 2():S17-9. PubMed ID: 17707641
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma.
    Zhang L; Yang N; Katsaros D; Huang W; Park JW; Fracchioli S; Vezzani C; Rigault de la Longrais IA; Yao W; Rubin SC; Coukos G
    Cancer Res; 2003 Jul; 63(14):4225-31. PubMed ID: 12874030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The emerging role of anti-angiogenic therapy in ovarian cancer (review).
    Conteduca V; Kopf B; Burgio SL; Bianchi E; Amadori D; De Giorgi U
    Int J Oncol; 2014 May; 44(5):1417-24. PubMed ID: 24626312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New ways to successfully target tumor vasculature in ovarian cancer.
    Yang X; Shen F; Hu W; Coleman RL; Sood AK
    Curr Opin Obstet Gynecol; 2015 Feb; 27(1):58-65. PubMed ID: 25502429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiogenesis inhibitors and the need for anti-angiogenic therapeutics.
    Dass CR; Tran TM; Choong PF
    J Dent Res; 2007 Oct; 86(10):927-36. PubMed ID: 17890668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identifying and targeting angiogenesis-related microRNAs in ovarian cancer.
    Chen X; Mangala LS; Mooberry L; Bayraktar E; Dasari SK; Ma S; Ivan C; Court KA; Rodriguez-Aguayo C; Bayraktar R; Raut S; Sabnis N; Kong X; Yang X; Lopez-Berestein G; Lacko AG; Sood AK
    Oncogene; 2019 Aug; 38(33):6095-6108. PubMed ID: 31289363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis.
    Edovitsky E; Elkin M; Zcharia E; Peretz T; Vlodavsky I
    J Natl Cancer Inst; 2004 Aug; 96(16):1219-30. PubMed ID: 15316057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
    Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
    Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Tumor angiogenesis: recent progress and remaining challenges].
    Feige JJ
    Bull Cancer; 2010 Nov; 97(11):1305-10. PubMed ID: 21051315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.